查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048180

胜肽類藥物偶聯物市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、類型、地區和競爭格局分類，2021-2031年

Peptide Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球胜肽類藥物偶聯物 (PDC) 市場預計將從 2025 年的 6.7102 億美元大幅成長至 2031 年的 14.6436 億美元，複合年成長率為 13.89%。

胜肽類藥物遞送系統（PDC）是一種先進的標靶治療，旨在將強效細胞毒性藥物直接遞送至特定的疾病受體位點。其原理是將獨特的肽段與細胞毒性有效載荷進行化學偶聯，從而顯著降低對健康組織的副作用。

市場概覽
預測期 2027-2031
市場規模：2025年 671,020,000 美元
市場規模：2031年 1,464,360,000 美元
複合年成長率：2026-2031年 13.89%
成長最快的細分市場 治療領域
最大的市場 北美洲

推動市場擴張的主要因素是對精準腫瘤治療日益成長的需求，與傳統化療相比，精準腫瘤治療可望降低全身毒性。全球癌症發生率的不斷攀升進一步凸顯了這些標靶治療的迫切性。例如，美國癌症協會估計，到2025年，美國將新增約2,041,910例癌症病例，凸顯了胜肽類藥物偶聯物（PDC）的重要作用。然而，肽類化合物本身不穩定，且由於腎臟快速清除，生物利用度低，這是市場成長的主要障礙。克服這些藥物動力學限制需要複雜的化學修飾，導致生產成本飆升和技術難度增加，使得新型胜肽類藥物偶聯物的廣泛商業性化應用和開發面臨挑戰。

市場促進因素

全球癌症和慢性疾病發生率的不斷攀升是推動全球胜肽類藥物偶聯物（PDC）市場發展的強大動力。隨著複雜疾病的日益普遍，人們對能夠以極高特異性遞送細胞毒性活性成分的療法的需求也日益成長。這種方法能夠有效減輕傳統治療方法常見的嚴重全身性副作用。各大衛生組織也強調了這種需求的迫切性。例如，美國癌症協會在2024年4月預測，在人口老化和成長的背景下，到2050年，全球新增癌症病例數可能達到每年3500萬例。這項預測的激增凸顯了PDC的巨大且不斷擴大的目標市場。 PDC尤其適用於標靶固態腫瘤和其他難以用大型抗體治療方法的惡性腫瘤。

同時，策略聯盟和夥伴關係正顯著加速這些複雜分子的臨床應用。製藥公司正加強對高價值授權協議和合資企業的參與力度，以獲取專有的胜肽平台和先進的連接子技術，從而有效地分擔研發過程中固有的巨大財務風險。例如，Bicycle Therapeutics公司報告稱，截至2024年9月30日的季度研發支出增至4,830萬美元，顯示其臨床管線推進需要高額的資本投入。為了抵​​消這些成本並利用外部專業知識，行業主要參與者正在建立廣泛的聯盟。例如，諾華公司與PeptiDream公司擴大了胜肽類藥物研發的合作關係，預計該合作的潛在價值將高達29億美元，凸顯了推動該領域創新的巨額資本流入。

市場挑戰

全球肽類藥物偶聯物市場面臨許多挑戰，包括肽類化合物固有的不穩定性以及快速的腎臟清除。由於天然胜肽易受酵素分解和排泄的影響，研發人員不得不進行複雜的化學修飾，以確保其在體內發揮持續的治療作用。這種大規模的分子工程需求大大增加了生產流程的技術複雜性，使原本較為簡單的合成變成了一項資源密集且高風險的工作，從而延緩了臨床研發的進展。

這些技術壁壘直接導致研發成本龐大，嚴重限制了能夠維持此類專案的製藥公司數量。克服這些藥物動力學限制所需的巨額資本投入，正在造成開發平臺的瓶頸。確保穩定性所帶來的巨大財務風險，導致從發現到商業化順利推進的候選療法數量減少。根據美國製藥製造商協會（PhRMA）預測，到2025年，開發一種新的複雜療法並將其推向市場的平均成本可能達到約26億美元。這一數字很大程度上受到應對技術挑戰和生產複雜性所需巨額資源的影響。這種財務負擔正在阻礙市場成長，減緩創新步伐，並限制這些新型偶聯物的商業化進程。

市場趨勢

將人工智慧 (AI) 應用於新型胜肽設計，正從根本上改變全球胜肽藥物偶聯物市場的藥物發現階段，有效應對低命中率和最佳化週期過長等傳統挑戰。透過利用先進的生成模型和深度學習演算法，開發人員現在甚至可以在物理合成之前，透過電腦預測具有顯著提高的結合親和性和穩定性特徵的胜肽結構。這種從經驗篩檢到理性設計的策略轉變將大大加速新型偶聯物的發現，特別是那些能夠靶向以往難以用藥物標靶化的受體的偶聯物。例如，2024 年 10 月，BioNTech 重點介紹了其專有的 AI 技術（包括 BFN 生成蛋白質模型）在其整個免疫療法產品線中的應用，以最佳化靶向癌症療法和抗體藥物複合體的開發。

同時，標靶放射性配體療法的快速商業化正在拓展市場格局，展現出胜肽介導的放射性同位素遞送在固態腫瘤治療的臨床優勢。這一趨勢的特點是，基於胜肽的放射性藥物在經過嚴格的臨床檢驗後，成功轉化為能夠產生豐厚利潤的重磅產品。反過來，這項成功也推動了對關鍵生產和供應鏈基礎設施的投資增加，以支持越來越多的患者獲得治療。為了佐證這一商業性勢頭，諾華在其2024年第三季中期財務報告（2024年10月）中披露，其基於胜肽的放射性配體療法Pluvicto的銷售額達到3.86億美元，年增50%。這反映了這些標靶偶聯物在現代腫瘤治療方法中的應用日益廣泛。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球胜肽類藥物偶聯物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品細分（鎦、Melflufen、ANG1005、BT1718、CBX-12 及其他研發線產品）
    • 按類型（治療、診斷）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美胜肽類藥物偶聯物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲胜肽類藥物偶聯物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區胜肽類藥物複合物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肽類藥物偶聯物的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美胜肽類藥物偶聯物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球胜肽類藥物偶聯物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG.
  • Bicycle Therapeutics PLC
  • AstraZeneca PLC
  • Cybrexa Therapeutics Inc
  • Oncopeptides Inc.
  • Angiochem Inc.
  • Innovasium Soricimed Biopharma
  • Theratechnologies Inc.
  • Coherent Biopharma Co. Ltd
  • Wuxi STA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16337

The Global Peptide Drug Conjugates (PDCs) Market is projected for substantial growth, anticipating an increase from USD 671.02 Million in 2025 to USD 1464.36 Million by 2031, at a Compound Annual Growth Rate (CAGR) of 13.89%. PDCs represent a sophisticated class of targeted therapeutics, engineered to deliver potent cytotoxic drugs directly to specific disease receptor sites. This is achieved by chemically linking a unique peptide moiety to a cytotoxic payload, thereby significantly minimizing adverse effects on healthy tissues.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 671.02 Million
Market Size 2031USD 1464.36 Million
CAGR 2026-203113.89%
Fastest Growing SegmentTherapeutic
Largest MarketNorth America

A primary catalyst for this market expansion is the increasing demand for precision oncology treatments that promise reduced systemic toxicity compared to conventional chemotherapy. The rising global prevalence of oncological disorders further underscores the urgent need for such targeted interventions. For instance, the American Cancer Society estimates approximately 2,041,910 new cancer cases in the United States in 2025, highlighting the critical role PDCs can play. However, market growth faces a significant impediment due to the inherent instability and rapid renal clearance of peptide-based compounds, which results in their short in vivo half-life. Overcoming these pharmacokinetic limitations necessitates complex chemical modifications, thereby escalating manufacturing costs and technical hurdles that challenge the widespread commercial adoption and development of novel peptide drug conjugates.

Market Driver

The escalating global incidence of oncology and chronic diseases serves as a powerful impetus for the Global Peptide Drug Conjugates Market. As complex health conditions become more prevalent, there is an intensifying demand for therapeutic agents capable of delivering cytotoxic payloads with exceptional specificity. This approach effectively mitigates the severe systemic side effects commonly associated with traditional treatments. The urgency of this need is substantiated by major health organizations; for example, the American Cancer Society predicted in April 2024 that new global cancer cases could reach 35 million annually by 2050, driven by population aging and growth. This projected surge underscores a critical and expanding addressable market for PDCs, which are uniquely suited to target solid tumors and other malignancies that prove challenging for larger antibody-based therapies.

Concurrently, strategic collaborations and partnerships are significantly accelerating the clinical translation of these intricate molecules. Pharmaceutical companies are increasingly engaging in high-value licensing agreements and joint ventures to gain access to proprietary peptide platforms and advanced linker technologies, effectively sharing the substantial financial risks inherent in research and development. For example, Bicycle Therapeutics reported a rise in R&D expenses to $48.3 million for the quarter ending September 30, 2024, illustrating the capital intensity required for clinical pipeline advancement. To offset such costs and leverage external expertise, major industry players are forging extensive deals, as exemplified by Novartis' expanded peptide discovery collaboration with PeptiDream, potentially valued at up to $2.9 billion, which highlights the massive capital influx driving innovation in this sector.

Market Challenge

The Global Peptide Drug Conjugates Market faces a formidable obstacle in the inherent instability and rapid renal clearance of peptide-based compounds. Native peptides are highly susceptible to quick enzymatic degradation and excretion, compelling developers to implement complex chemical modifications to achieve an adequate therapeutic duration within the body. This extensive molecular engineering requirement substantially increases the technical complexity of the manufacturing process, transforming what could be a simpler synthesis into a resource-intensive and high-risk undertaking that slows down clinical progress.

These technical barriers directly contribute to exorbitant research and development expenditures, significantly limiting the number of pharmaceutical entities capable of sustaining such programs. The high capital investment necessary to overcome these pharmacokinetic limitations creates a bottleneck in the development pipeline, as fewer candidate therapies successfully advance from discovery to commercialization due to the considerable financial risks associated with ensuring stability. According to the Pharmaceutical Research and Manufacturers of America, the average cost to develop and launch a new complex therapeutic could reach approximately $2.6 billion by 2025, a figure heavily influenced by the extensive resources required to address technical hurdles and manufacturing complexities. This financial burden hinders market growth by decelerating innovation and restricting the commercial availability of these novel conjugates.

Market Trends

The integration of Artificial Intelligence (AI) for de novo peptide design is fundamentally transforming the discovery phase of the Global Peptide Drug Conjugates Market, effectively addressing historical challenges such as low hit rates and protracted optimization cycles. By leveraging advanced generative models and deep learning algorithms, developers are now able to computationally predict peptide structures with significantly improved binding affinity and stability profiles even before physical synthesis. This strategic shift from empirical screening to rational design markedly accelerates the identification of novel conjugates, particularly those capable of targeting previously undruggable receptors. For instance, BioNTech highlighted in October 2024 the deployment of its proprietary AI capabilities, including the BFN generative protein model, across its immunotherapy pipeline to optimize the development of targeted cancer treatments and antibody-drug conjugates.

Concurrently, the rapid commercialization of targeted radioligand therapies is expanding the commercial landscape of the market, demonstrating the clinical superiority of peptide-mediated delivery of radioactive isotopes in treating solid tumors. This trend is characterized by the successful transition of peptide-based radiopharmaceuticals from rigorous clinical validation to becoming revenue-generating blockbuster assets. This success is, in turn, driving increased investment in essential manufacturing and supply chain infrastructure to support growing patient access. Validating this commercial momentum, Novartis reported in its Q3 2024 Interim Financial Report (October 2024) that sales of its peptide-based radioligand therapy, Pluvicto, surged by 50% year-over-year, reaching $386 million, reflecting the escalating adoption of these targeted conjugates in contemporary oncology regimens.

Key Market Players

  • Novartis AG.
  • Bicycle Therapeutics PLC
  • AstraZeneca PLC
  • Cybrexa Therapeutics Inc
  • Oncopeptides Inc.
  • Angiochem Inc.
  • Innovasium Soricimed Biopharma
  • Theratechnologies Inc.
  • Coherent Biopharma Co. Ltd
  • Wuxi STA

Report Scope

In this report, the Global Peptide Drug Conjugates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Drug Conjugates Market, By Product

  • Lutetium
  • Melflufen
  • ANG1005
  • BT1718
  • CBX-12
  • Other Pipeline Products

Peptide Drug Conjugates Market, By Type

  • Therapeutic
  • Diagnostic

Peptide Drug Conjugates Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Drug Conjugates Market.

Available Customizations:

Global Peptide Drug Conjugates Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Drug Conjugates Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline Products)
    • 5.2.2. By Type (Therapeutic, Diagnostic)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Peptide Drug Conjugates Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Peptide Drug Conjugates Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Type
    • 6.3.2. Canada Peptide Drug Conjugates Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Type
    • 6.3.3. Mexico Peptide Drug Conjugates Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Type

7. Europe Peptide Drug Conjugates Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Peptide Drug Conjugates Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Type
    • 7.3.2. France Peptide Drug Conjugates Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Type
    • 7.3.3. United Kingdom Peptide Drug Conjugates Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Type
    • 7.3.4. Italy Peptide Drug Conjugates Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Type
    • 7.3.5. Spain Peptide Drug Conjugates Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Type

8. Asia Pacific Peptide Drug Conjugates Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Peptide Drug Conjugates Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Type
    • 8.3.2. India Peptide Drug Conjugates Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Type
    • 8.3.3. Japan Peptide Drug Conjugates Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Type
    • 8.3.4. South Korea Peptide Drug Conjugates Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Type
    • 8.3.5. Australia Peptide Drug Conjugates Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Type

9. Middle East & Africa Peptide Drug Conjugates Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Peptide Drug Conjugates Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Type
    • 9.3.2. UAE Peptide Drug Conjugates Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Type
    • 9.3.3. South Africa Peptide Drug Conjugates Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Type

10. South America Peptide Drug Conjugates Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Peptide Drug Conjugates Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Type
    • 10.3.2. Colombia Peptide Drug Conjugates Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Type
    • 10.3.3. Argentina Peptide Drug Conjugates Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Peptide Drug Conjugates Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bicycle Therapeutics PLC
  • 15.3. AstraZeneca PLC
  • 15.4. Cybrexa Therapeutics Inc
  • 15.5. Oncopeptides Inc.
  • 15.6. Angiochem Inc.
  • 15.7. Innovasium Soricimed Biopharma
  • 15.8. Theratechnologies Inc.
  • 15.9. Coherent Biopharma Co. Ltd
  • 15.10. Wuxi STA

16. Strategic Recommendations

17. About Us & Disclaimer